Portuguese 
English 
Spanish 
5 min of reading 
0 comments 
Changes in Diagnostic Guidelines Bring TDP-43 (LATE) to Attention: It Affects More Than 10% of Older Adults over 65 and Can Imitate Alzheimer’s, with Memory Loss and Signs of Dementia.
A Confusion That Could Change Everything! If you know someone who has started to forget things frequently, has become more disoriented, and soon the suspicion of Alzheimer’s arose, know that there is another explanation gaining traction in medicine. Researchers and health authorities are drawing attention to a condition that has been recognized more clearly in recent years, precisely because it looks very much like Alzheimer’s “on the outside,” but has a different signature in the brain. The name is TDP-43 Encephalopathy, also known as LATE.
What’s Behind the New Alert
With aging, it is common for health problems related to changes in the body and a decline in the immune system to arise. However, attention has now turned to a diagnosis that has been better defined by new clinical guidelines.
LATE (short for “Limbic Predominant Age-Related TDP-43 Encephalopathy”) has come to be recognized as an important syndrome among older adults, as it appears with significant frequency after the age of 65.
-
Worlds covered by water, atmospheres filled with hydrogen, and the possibility of life beyond Earth: ocean planets are rewriting the map of cosmic search and forcing scientists to rethink where to look.
-
Argentina achieves the unimaginable after more than 110 years and reintroduces the largest native herbivore of South America to the Chaco to restore a lost link in nature.
-
Returning to the Moon now costs a billion-dollar bill and reignites the competition between the USA and China for science, technology, and rare minerals on lunar soil.
-
While the world looks at oil, the war with Iran is already disrupting helium supply from Qatar, affecting car and iPhone chips, threatening AI expansion, and putting pressure on aluminum packaging at the highest value in four years.
Estimates cited by academic centers indicate that LATE, with or without the coexistence of typical Alzheimer’s changes, affects more than 10% of individuals over 65 years.
And, among the very elderly, the number rises significantly, reaching around 25% to 40% in people aged 85 or older.
In publications and research statements, it is also highlighted that it may affect more than one-third of individuals over the age of 85.
What Studies Have Observed Since 2018
The central point is that LATE is associated with a cognitive decline resembling Alzheimer’s: the person may exhibit memory loss and signs of dementia.
The basis for these conclusions comes from research analyzing data from brain autopsies and previous studies — an important pathway because, historically, many of these conditions are only 100% confirmed through neuropathological evaluation.
In other words: it’s not that it “appeared out of nowhere.” What changed was the level of recognition and the organization of criteria to better see the problem.
Why Do So Many People Think It’s Alzheimer’s?
Here comes a noteworthy detail: many people arrive at the doctor’s office believing that Alzheimer’s is the primary cause of memory deterioration. However, part of these cases may be “disguised.”
In an institutional publication linked to the reference center at the University of Kentucky, neurologist Greg Jicha got straight to the point when discussing clinical experience: “In about one in five patients who come to our clinic, what was previously thought to be Alzheimer’s actually appears to be LATE.” In practice, he sums up the challenge: “It can clinically resemble Alzheimer’s — they have a memory problem.”
This helps explain why the diagnosis can be so confusing in everyday life, especially when the evaluation is based solely on symptoms.
The Cause Remains a Mystery, but Risk May Increase with APOE4
Despite the advancement of research, the exact cause of LATE remains an unknown. Nonetheless, there is already a risk factor that frequently appears in scientific discussions: the genetic variant Apolipoprotein E4 (APOE4).
The point is that APOE4 is also related to the risk of Alzheimer’s and may connect to a greater propensity for vascular conditions.
So, when it comes to increased risk, the message is simple: older adults are already the most vulnerable group by age, and some genetic profiles may further elevate this probability.
LATE “Pure” vs. Alzheimer’s: What Really Changes?
The symptoms may be similar, but there are important differences.
When LATE appears “alone,” it tends to be less aggressive than conventional Alzheimer’s.
On the other hand, when both conditions coexist, the situation can accelerate and become much more severe, with a quicker and more aggressive decline. In this scenario, complications such as psychosis and urinary incontinence may arise.
In practice, it can be summarized like this.
In Alzheimer’s, it is common to see impairment not only in memory but also in planning, organization, and execution of daily tasks.
On the other hand, in LATE, the situation usually focuses more on memory loss and difficulty in finding and naming objects.
The difference also appears at the biological level. While Alzheimer’s involves amyloid plaques and tau protein, LATE is associated with abnormal accumulations of TDP-43 protein, which is precisely the “signature” of this Encephalopathy.
How Diagnosis Comes Into Play Today
Despite all the progress, there is a sensitive point: it is still difficult to definitively diagnose LATE in living individuals, and therefore specialists work with combinations of clues.
Generally, the evaluation may involve brain imaging (with an emphasis on changes in the hippocampus and areas linked to memory), tests, and biomarkers focused on Alzheimer’s pathology, and, primarily, a careful analysis: do the cognitive symptoms seem more like LATE than Alzheimer’s?
This is not a bureaucratic detail. It is a difference that can directly influence clinical decisions.
An Important Treatment Alert: Not Every “Alzheimer’s Drug” Makes Sense Here
In the foundational text, there is an essential point that deserves to be made very clear: patients with LATE should not be treated as if they have Alzheimer’s when there is no evidence of amyloid.
This is because part of the most modern Alzheimer’s treatments is designed to target specific targets, such as beta-amyloid protein.
Today, for example, there are anti-amyloid therapies (monoclonal antibodies) aimed at removing or reducing amyloid plaques in the brain.
Therefore, if the patient does not have this target (that is, if tests do not indicate amyloid), the treatment logic changes completely.
Thus, when the diagnosis points more towards LATE than Alzheimer’s, the approach needs to be adjusted carefully, to avoid strategies that aim at a mechanism that is not present in that case.
What You Can Take Away from All This
The discussion surrounding LATE is growing precisely because it helps explain a part of the cases where the clinical history seems like Alzheimer’s, but the brain’s biology tells a different story.
For older adults and families, this means a very objective thing: insisting on careful evaluation, with biomarker investigation when indicated, can avoid inaccurate diagnoses and better guide the next steps.
If you have someone in your family over 65 years old facing health problems related to memory, it’s worth bringing this conversation to the doctor and asking calmly and without paranoia: “Is there a chance it could be another condition besides Alzheimer’s, like LATE?”
Have you heard of this Encephalopathy (LATE) or seen someone treated as Alzheimer’s without much certainty? Leave a comment with your experience and share this publication with those who care for older adults — this may help more people seek the correct diagnosis.
Seja o primeiro a reagir!